MoonLake Immunotherapeutics (MLTX) Net Income towards Common Stockholders (2021 - 2026)

MoonLake Immunotherapeutics' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$69.7 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 71.87% year-over-year to -$69.7 million; the TTM figure through Mar 2026 stood at -$259.5 million (down 75.52% YoY), while the FY2025 annual figure was -$230.3 million, down 89.96% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$69.7 million, down from -$63.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$7.9 million in Q4 2023, with the low at -$70.7 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$17.4 million (2022), against an average of -$31.2 million.
• Peak annual rise in Net Income towards Common Stockholders reached 69.3% in 2022, while the deepest fall reached 20715.22% in 2022.
• MoonLake Immunotherapeutics' Net Income towards Common Stockholders stood at -$16.5 million in 2022, then soared by 52.11% to -$7.9 million in 2023, then plunged by 488.23% to -$46.4 million in 2024, then sank by 35.83% to -$63.0 million in 2025, then fell by 10.61% to -$69.7 million in 2026.
• Business Quant data shows MLTX's Net Income towards Common Stockholders at -$69.7 million in Q1 2026, -$63.0 million in Q4 2025, and -$70.7 million in Q3 2025.